SV Health Investors

SV Health Investors, established in 1993, is a prominent venture capital firm headquartered in Boston, Massachusetts. With over $2 billion in assets under management across seven private healthcare funds, the firm invests in innovative healthcare and life sciences companies across the United States and Europe. SV Health Investors focuses on supporting entrepreneurs developing breakthrough treatments and technologies, with a particular interest in therapeutics, biotechnology, healthcare services, and medical technology. The firm aims to transform healthcare through strategic investments, leveraging its 20-year track record and offices in Boston, San Francisco, and London.

Jonathan Behr

Partner

Kate Bingham

Managing Partner

Hamish Cameron

Operating Partner

Andrew Cappetta

Associate

James Costine

Partner and Co-CFO (UK) and Chief Risk Officer

Charles Dunn

Principal

Freya Easton

Associate

Georgia Frost Ph.D

Senior Associate

Emily Gaudiano

Associate

Lynne Hughes Ph.D

Venture Partner

Ray Jupp Ph.D

Venture Partner

Dirk Landgraf

Vice President

Megan MacDonagh

Vice President

Duncan McHale

Venture Partner

Alfred Rossi

Principal

James Summers Ph.D

Venture Partner

Barbara Tate Ph.D

Venture Partner

Nikola Trbovic

Partner

Iain Kilty Ph.D

Venture Partner

A.J. Rossi

Principal

Past deals in Medical

Imbria Pharmaceuticals

Series B in 2025
Imbria Pharmaceuticals, Inc. is a clinical-stage pharmaceuticals company based in Boston, Massachusetts, founded in 2018. The company specializes in developing innovative therapies aimed at addressing cardiometabolic disorders by enhancing or restoring cellular energy production. Imbria's research focuses on the mechanisms underlying these conditions, particularly in areas such as non-obstructive hypertrophic cardiomyopathy, stable angina, and heart failure with preserved ejection fraction. By translating scientific insights into practical treatments, Imbria Pharmaceuticals aims to meet significant unmet medical needs and improve the lives of patients affected by these life-altering disorders. Through its commitment to understanding cellular metabolism and mitochondrial function, the company works to advance healthcare solutions in the cardiometabolic space.

Perfuze

Venture Round in 2025
Perfuze is a neurovascular medical device company based in Galway, Ireland, established in 2018. The company specializes in developing innovative catheter technology aimed at treating acute ischemic stroke. By utilizing its proprietary catheter-based aspiration platform, Perfuze focuses on optimizing the efficiency of clot removal, which in turn seeks to enhance clinical outcomes and reduce procedural times. This technology aims to simplify the treatment process while minimizing the need for alternative interventions, providing patients with a cost-effective solution for ischemic stroke therapy.

Ria Health

Series B in 2025
Ria Health is an online platform that provides telehealth services for individuals looking to improve their relationship with alcohol. It offers personalized treatment plans that include medication-assisted treatment options and behavioral therapies, all supported by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability in their recovery journey. Ria Health features a mobile app that grants users access to educational materials, support groups, and direct communication with care teams. This comprehensive approach aims to assist individuals in managing alcohol consumption and fostering healthier habits.

AdvanCell

Series C in 2025
AdvanCell is a clinical-stage radiopharmaceutical company focused on developing innovative cancer therapies. The company specializes in alpha-emitting isotopes, specifically 212Pb, which are attached to molecules that target tumors directly. This approach allows for the delivery of cytotoxic radiation at the molecular level, addressing significant challenges in targeted alpha therapy regarding supply reliability and scalability. By providing safe and effective treatments for various forms of cancer, AdvanCell aims to establish its therapies as a standard of care in oncology.

Enara Bio

Series B in 2024
Enara Bio is a biotechnology company based in Oxford, United Kingdom, focused on developing vaccines and immunotherapies for cancer treatment and prevention. Founded in 2016, the company specializes in identifying and utilizing novel antigens derived from endogenous retroviral DNA sequences to create therapeutic cancer vaccines. Enara Bio's technology platform enables the exploration of dark antigens, assessing their tumor specificity and immunogenic potential, which is crucial for effective cancer therapies. The company's innovative approach targets the interaction between T-cells and cancer cells, aiming to create targeted immunotherapies that can benefit a broad patient population.

CSA Medical

Series D in 2024
CSA Medical, Inc. specializes in the development and manufacturing of spray cryotherapy medical devices. The company's flagship product, the truFreeze device, utilizes cold liquid nitrogen as a cryosurgical tool for the destruction of unwanted tissue in dermatology, gynecology, and general surgery, while facilitating the regrowth of healthy tissue. Additionally, CSA Medical offers the Rapid AV Spray Kit, which enhances the truFreeze system by reducing the time required for liquid nitrogen application. Originally founded as Crymed Technologies in 1993, the company rebranded to CSA Medical in April 2006. Headquartered in Lutherville Timonium, Maryland, CSA Medical also operates a research and development facility in Lexington, Massachusetts.

Spineology

Series A in 2024
Spineology Inc. is a medical technology company that specializes in anatomy-conserving solutions for spine surgery. Founded in 1996 and based in Saint Paul, Minnesota, the company offers a range of products including pedicular fixation systems such as Threshold and Fortress, spinal fixation systems like CapLOX II, and biological products including Prime, a liquid tissue matrix, and Armor, an allograft for wound covering. Their portfolio also features interbody fusion systems like Rampart O and Rampart T, as well as instruments for facet fixation, spinous process fixation, and retraction systems such as Medius and SOAR. Additionally, Spineology provides ProMap, an EMG navigation system, and OptiMesh, a graft containment solution. The company’s innovations enable healthcare professionals to perform minimally invasive surgeries, enhancing procedural efficiency and improving patient recovery outcomes.

Brixton Biosciences

Series B in 2024
Brixton Biosciences is a clinical-stage life sciences company focused on developing innovative therapies for chronic and acute pain management. The company aims to address significant unmet needs in this area, which has traditionally relied on systemic medications. Its flagship product, Neural Ice™, is a drug-free injectable treatment designed to induce reversible inhibition of nerves, offering a non-addictive, locally targeted solution. This therapy provides patients with extended pain relief lasting from thirty to sixty days following a single injection, representing a significant advancement over current pain management methods.

Miach Orthopaedics

Series B in 2024
Miach Orthopaedics is a medical device company based in Westborough, Massachusetts, founded in 2016. The company specializes in developing bio-engineered surgical implants aimed at facilitating new tissue growth and aiding in connective tissue repair. Its primary product, the Bridge-Enhanced ACL Repair technology, offers a viable alternative to traditional anterior cruciate ligament (ACL) reconstruction for patients who have suffered ACL injuries. This innovative approach enables surgeons to restore the normal anatomy and function of the knee, enhancing recovery outcomes for patients.

BioAge Labs

Series D in 2024
BioAge Labs, Inc. is a biotechnology company focused on developing therapies to address aging and age-related diseases. The company utilizes a systems biology and artificial intelligence platform to identify key drug targets that influence aging and analyze extensive datasets to uncover the molecular drivers of age-related conditions. BioAge Labs is advancing several drug candidates, including BGE-117, a hypoxia-inducible factor prolyl hydroxylase inhibitor designed to activate genes involved in critical biological processes such as tissue regeneration and vascular remodeling. Additionally, BGE-175, an orally administered inhibitor of the prostaglandin D2 DP1 signaling pathway, aims to mitigate risks associated with immune aging and respiratory infections. Founded in 2015 and based in Richmond, California, BioAge Labs is committed to discovering and developing innovative treatments that harness the biology of human aging.

Harness Therapeutics

Seed Round in 2023
Harness Therapeutics is a biotechnology company dedicated to developing a novel class of therapeutic RNAs known as SINEUPs®, which allow for precise upregulation of protein expression. This innovative technology provides a unique mechanism of action aimed at addressing challenging diseases, significantly broadening the druggable proteome. Harness Therapeutics focuses on central nervous system and ophthalmologic disorders but also sees potential applications across various therapeutic areas. By enhancing translation, their platform meets unmet medical needs and enables the creation of differentiated products that cannot be achieved with existing technologies.

Eyebiotech

Series A in 2023
Eyebiotech is a vision treatment company that develops products to preserve, repair, and improve eyesight. The firm guards against sight-threatening eye disorders and developed the first anti-vascular endothelial growth factor medication for patients with age-related macular degeneration, allowing those with eye ailments to regain their eyesight.

Nimbus Therapeutics

Private Equity Round in 2023
Nimbus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company utilizes advanced computational technologies to create selective and potent small-molecule therapeutics. Among its notable projects is the Nimbus Apollo program, which features the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase (ACC). This compound is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and has potential applications in hepatocellular carcinoma (HCC) and other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, highlighting its significance in the clinical development pipeline. Nimbus Therapeutics has formed strategic partnerships to enhance its research and development capabilities, reinforcing its commitment to advancing treatment options for complex health challenges.

Therini Bio

Series A in 2023
Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies aimed at treating inflammatory neurological and retinal diseases. The company leverages insights from research that highlights the role of fibrin in driving chronic innate immune activation, which is implicated in various human diseases with significant unmet medical needs. Currently, Therini Bio is working on therapeutics that aim to protect the nervous system from damage associated with conditions such as multiple sclerosis. By developing specialized antibodies for neuroinflammatory diseases linked to vascular dysfunction, the company seeks to provide healthcare providers with effective treatment options that can improve patient outcomes.

Pulmocide

Series C in 2022
Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.

Alpheus Medical

Series A in 2022
Alpheus Medical specializes in developing innovative treatment solutions for solid body cancers, focusing primarily on aggressive brain tumors. The company has created a novel sonodynamic therapy platform that employs a non-invasive drug-device combination for the outpatient treatment of recurrent glioblastoma multiforme (rGBM). This approach utilizes photodynamic therapy, which involves using light delivered through a minimally invasive device to target cancer cells that have been exposed to a photosensitizer. By offering these advanced therapeutic options, Alpheus Medical aims to provide effective alternatives to traditional invasive brain surgeries, enhancing patient care and treatment outcomes.

Nimbus Therapeutics

Venture Round in 2022
Nimbus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company utilizes advanced computational technologies to create selective and potent small-molecule therapeutics. Among its notable projects is the Nimbus Apollo program, which features the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase (ACC). This compound is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and has potential applications in hepatocellular carcinoma (HCC) and other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, highlighting its significance in the clinical development pipeline. Nimbus Therapeutics has formed strategic partnerships to enhance its research and development capabilities, reinforcing its commitment to advancing treatment options for complex health challenges.

Ria Health

Series A in 2022
Ria Health is an online platform that provides telehealth services for individuals looking to improve their relationship with alcohol. It offers personalized treatment plans that include medication-assisted treatment options and behavioral therapies, all supported by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability in their recovery journey. Ria Health features a mobile app that grants users access to educational materials, support groups, and direct communication with care teams. This comprehensive approach aims to assist individuals in managing alcohol consumption and fostering healthier habits.

ViTToria Biotherapeutics

Seed Round in 2022
ViTToria Biotherapeutics specializes in developing gene-edited cell therapies, focusing on next-generation T-cell therapeutics that aim to address significant unmet medical needs. The company’s proprietary Senza5 Technology enhances the efficacy, safety, and utility of these cell-based treatments in preclinical settings. By improving dosing requirements, simplifying preconditioning regimens, minimizing manufacturing failures, and reducing the time from production to patient administration, ViTToria Biotherapeutics enables healthcare providers to achieve better patient outcomes. The innovative approach of the company positions it as a leader in the evolving field of cell therapies.

Rondo Therapeutics

Series A in 2022
Rondo Therapeutics is a biotechnology company focused on the discovery and development of novel bispecific antibodies aimed at activating the immune system to combat cancer. Founded in 2021 and based in Hayward, California, the company specializes in creating cancer immunotherapies specifically for solid tumor types that do not respond to conventional immune checkpoint inhibitors. By targeting areas of unmet medical need, Rondo Therapeutics enables researchers to advance innovative drug solutions in the fight against cancer.

Eyebiotech

Series A in 2022
Eyebiotech is a vision treatment company that develops products to preserve, repair, and improve eyesight. The firm guards against sight-threatening eye disorders and developed the first anti-vascular endothelial growth factor medication for patients with age-related macular degeneration, allowing those with eye ailments to regain their eyesight.

Perfuze

Series A in 2022
Perfuze is a neurovascular medical device company based in Galway, Ireland, established in 2018. The company specializes in developing innovative catheter technology aimed at treating acute ischemic stroke. By utilizing its proprietary catheter-based aspiration platform, Perfuze focuses on optimizing the efficiency of clot removal, which in turn seeks to enhance clinical outcomes and reduce procedural times. This technology aims to simplify the treatment process while minimizing the need for alternative interventions, providing patients with a cost-effective solution for ischemic stroke therapy.

Quell Therapeutics

Series B in 2021
Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions. Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.

Alpheus Medical

Series A in 2021
Alpheus Medical specializes in developing innovative treatment solutions for solid body cancers, focusing primarily on aggressive brain tumors. The company has created a novel sonodynamic therapy platform that employs a non-invasive drug-device combination for the outpatient treatment of recurrent glioblastoma multiforme (rGBM). This approach utilizes photodynamic therapy, which involves using light delivered through a minimally invasive device to target cancer cells that have been exposed to a photosensitizer. By offering these advanced therapeutic options, Alpheus Medical aims to provide effective alternatives to traditional invasive brain surgeries, enhancing patient care and treatment outcomes.

Zerigo Health

Series B in 2021
Zerigo Health, formerly known as Clarify Medical, Inc., specializes in home therapy solutions for chronic skin conditions such as psoriasis, eczema, and vitiligo. The company offers innovative products like the Clarify mobile ultra violet B treatment system and the Home Light Therapy System, both designed to facilitate phototherapy in a home setting. Zerigo Health aims to enhance the ease and effectiveness of UVB therapy through a connected system that allows patients to manage their treatment via a smartphone app. This app enables users to control dosing, frequency, and duration of therapy, ensuring adherence to guidelines set by dermatology experts. By allowing patients to administer their treatments with clinical precision, Zerigo Health improves the overall patient experience, while also monitoring compliance and progress, ultimately empowering individuals to manage their chronic skin conditions more effectively from the comfort of their homes.

Eyebiotech

Seed Round in 2021
Eyebiotech is a vision treatment company that develops products to preserve, repair, and improve eyesight. The firm guards against sight-threatening eye disorders and developed the first anti-vascular endothelial growth factor medication for patients with age-related macular degeneration, allowing those with eye ailments to regain their eyesight.

Artios Pharma

Series C in 2021
Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2015, the company is dedicated to creating first-in-class therapies aimed at selectively killing cancer cells. Artios's product pipeline features several promising programs, including a focus on DNA polymerase theta (Polθ), which plays a crucial role in DNA repair processes. Additionally, the company is advancing an in-licensed program that targets a newly identified protein linked to DDR and is developing a novel treatment aimed at DNA nucleases involved in these pathways. Artios collaborates with Cancer Research Technology and prominent DNA repair researchers globally to enhance its research and development efforts.

Pulmocide

Series C in 2021
Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.

Therini Bio

Seed Round in 2021
Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies aimed at treating inflammatory neurological and retinal diseases. The company leverages insights from research that highlights the role of fibrin in driving chronic innate immune activation, which is implicated in various human diseases with significant unmet medical needs. Currently, Therini Bio is working on therapeutics that aim to protect the nervous system from damage associated with conditions such as multiple sclerosis. By developing specialized antibodies for neuroinflammatory diseases linked to vascular dysfunction, the company seeks to provide healthcare providers with effective treatment options that can improve patient outcomes.

Mestag Therapeutics

Seed Round in 2021
Mestag Therapeutics is a biotechnology company focused on developing innovative therapies for cancer and inflammatory diseases. Utilizing a research and development platform that leverages insights into the role of activated fibroblast populations in disease, the company aims to create therapeutics that target fibroblast-mediated effects on immune cells. This approach is designed to enhance the medical industry's ability to combat and potentially cure rare and life-threatening conditions. Through its work, Mestag Therapeutics seeks to contribute meaningful advancements in the treatment landscape for these challenging diseases.

Xilio Therapeutics

Series C in 2021
Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

Leiters Health

Seed Round in 2020
Leiters is an FDA-registered 503B outsourcing provider specializing in high-quality ophthalmology and hospital-based services. The company focuses on delivering compounded sterile preparations to hospitals, surgery centers, and physician offices. Its extensive portfolio includes ready-to-administer products such as pre-filled syringes, vials, bags, and injectable compounds, along with opioid-free surgical pain services and various ophthalmic solutions. With a team of experts in sterile pharmaceutical manufacturing, repackaging, and compounding, Leiters is dedicated to ensuring quality and consistency in its offerings. The company has a long-standing commitment to patient health and has served healthcare professionals for nearly a century, reinforcing its reputation for reliability in providing critically needed outsourced medications.

Catamaran Bio

Series A in 2020
Catamaran Bio is a biotechnology company focused on developing allogeneic immune cell therapies, specifically CAR-NK cell therapies, aimed at treating solid tumors and other cancers. The company utilizes its Tailwind platform to engineer, expand, and process natural killer (NK) cells into off-the-shelf therapeutic products that can address significant unmet medical needs. Founded in 2019 and headquartered in Cambridge, Massachusetts, Catamaran Bio is committed to providing transformative treatments through genetic engineering of NK cells, enabling easier access for medical practitioners and patients in need of effective cancer therapies.

AavantiBio

Series A in 2020
AavantiBio, Inc. is a biopharmaceutical company based in Gainesville, Florida, focused on developing gene transfer and gene editing therapies for rare genetic diseases. Established in 2019, the company primarily targets Friedreich’s Ataxia, a severe inherited condition that leads to significant cardiac and central nervous system dysfunction. In addition to addressing this specific disorder, AavantiBio is advancing a pipeline of innovative gene therapies aimed at treating various autoimmune diseases and other conditions with unmet medical needs. Through its commitment to research and development, the company seeks to improve the lives of patients affected by these debilitating genetic disorders.

Alchemab Therapeutics

Series A in 2020
Alchemab Therapeutics Ltd is a biotechnology company based in London, established in 2019 by Uri Laserson and Jane Osbourn. The company focuses on discovering and developing novel therapeutics that utilize naturally protective antibodies to combat hard-to-treat diseases, including certain cancers, neurodegenerative conditions, and infectious diseases. Alchemab employs an unbiased, function-first approach to identify drug targets, leveraging three complementary processes and technologies to create a robust pipeline of antibody therapeutics. By harnessing these naturally occurring antibodies, Alchemab aims to provide innovative treatment options for patients facing challenging medical conditions.

Cellinta

Seed Round in 2020
Cellinta Limited is a biotechnology company based in London, United Kingdom, that focuses on the research and development of gene therapies, specifically targeting cancer treatments. Founded in 2019 and originally known as Biotech 2 Ltd, the company has developed a platform that enables the selective elimination of neural stem cells and brain cancers. Cellinta's innovative approach includes the creation of computational tools and patient-derived cancer stem cell models to identify regulatory circuits specific to cancer stem cells. This technology facilitates the selective delivery of anti-cancer therapies, simultaneously obstructing multiple pathways essential for tumor growth and enhancing immune response. Through its pioneering work, Cellinta aims to advance the medical community's efforts in combating solid tumors.

Xilio Therapeutics

Series B in 2020
Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

CytoMed Therapeutics

Venture Round in 2020
CytoMed Therapeutics is a pre-clinical biopharmaceutical company that originated as a spin-off from Singapore's Agency for Science, Technology, and Research (A*Star). The company specializes in developing "off-the-shelf" immunotherapeutics using gamma delta T cells and natural killer (NK) cells to address various types of tumors. CytoMed also produces induced pluripotent stem cells (iPSCs) and transforms them into cellular medicines for its clients using proprietary technology. The company's innovations are inspired by the success of CAR-T cell therapies for hematological malignancies, while also addressing the challenges faced in applying CAR-T principles to solid tumors. CytoMed primarily operates in Singapore and Malaysia, which contribute significantly to its revenue.

Caraway Therapeutics

Venture Round in 2020
Caraway Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments for neurodegenerative diseases through the modulation of mitophagy and autophagy. By targeting genetically defined pathways, the company aims to create small molecules that restore cellular balance and address the underlying mechanisms of diseases such as Parkinson's disease and amyotrophic lateral sclerosis. Founded in 2018 and based in Cambridge, Massachusetts, Caraway Therapeutics seeks to improve the lives of patients affected by these debilitating conditions by leveraging its expertise in cellular degradation processes. The company was previously known as Rheostat Therapeutics, Inc. before rebranding in October 2019.

Transposon

Seed Round in 2020
Transposon Therapeutics is a pharmaceutical company based in Westport, Connecticut, focused on developing innovative therapeutics for debilitating and life-threatening diseases, particularly neurodegenerative disorders and diseases associated with aging. The company is in the clinical stage and is engaged in the research and development of nucleoside inhibitors targeting LINE-1 reverse transcriptase and other mediators linked to LINE-1 pathology. By addressing these critical areas, Transposon Therapeutics aims to provide effective treatment options for patients suffering from conditions that significantly impact their quality of life.

EBT Medical

Series A in 2019
EBT Medical, Inc. is a clinical-stage company focused on developing non-invasive neuromodulation therapies for pelvic health disorders, particularly targeting overactive bladder issues. Founded in 2014 and headquartered in Boston, Massachusetts, with an additional office in Toronto, Canada, the company emerged from scientific research conducted at the University of Toronto. EBT Medical's innovative technology aims to provide discreet treatment options that restore pelvic health function without the side effects commonly associated with traditional therapies. The company is part of a broader ecosystem designed to support patients with pelvic floor disorders.

Enara Bio

Series A in 2019
Enara Bio is a biotechnology company based in Oxford, United Kingdom, focused on developing vaccines and immunotherapies for cancer treatment and prevention. Founded in 2016, the company specializes in identifying and utilizing novel antigens derived from endogenous retroviral DNA sequences to create therapeutic cancer vaccines. Enara Bio's technology platform enables the exploration of dark antigens, assessing their tumor specificity and immunogenic potential, which is crucial for effective cancer therapies. The company's innovative approach targets the interaction between T-cells and cancer cells, aiming to create targeted immunotherapies that can benefit a broad patient population.

Zerigo Health

Series A in 2019
Zerigo Health, formerly known as Clarify Medical, Inc., specializes in home therapy solutions for chronic skin conditions such as psoriasis, eczema, and vitiligo. The company offers innovative products like the Clarify mobile ultra violet B treatment system and the Home Light Therapy System, both designed to facilitate phototherapy in a home setting. Zerigo Health aims to enhance the ease and effectiveness of UVB therapy through a connected system that allows patients to manage their treatment via a smartphone app. This app enables users to control dosing, frequency, and duration of therapy, ensuring adherence to guidelines set by dermatology experts. By allowing patients to administer their treatments with clinical precision, Zerigo Health improves the overall patient experience, while also monitoring compliance and progress, ultimately empowering individuals to manage their chronic skin conditions more effectively from the comfort of their homes.

CSA Medical

Venture Round in 2019
CSA Medical, Inc. specializes in the development and manufacturing of spray cryotherapy medical devices. The company's flagship product, the truFreeze device, utilizes cold liquid nitrogen as a cryosurgical tool for the destruction of unwanted tissue in dermatology, gynecology, and general surgery, while facilitating the regrowth of healthy tissue. Additionally, CSA Medical offers the Rapid AV Spray Kit, which enhances the truFreeze system by reducing the time required for liquid nitrogen application. Originally founded as Crymed Technologies in 1993, the company rebranded to CSA Medical in April 2006. Headquartered in Lutherville Timonium, Maryland, CSA Medical also operates a research and development facility in Lexington, Massachusetts.

myOrthos

Seed Round in 2019
myOrthos is an orthodontic support platform designed to assist orthodontists and their teams in enhancing patient care and fostering a community of orthodontic excellence. The platform offers a comprehensive range of services, including office management, billing and collections, capital management, and succession planning. By partnering with orthodontic practices, myOrthos addresses various challenges related to practice transitions, while also providing marketing support and staff recruitment and training. This holistic approach enables orthodontists to focus on delivering high-quality care to their patients while efficiently managing their practice operations.

Caraway Therapeutics

Series A in 2018
Caraway Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments for neurodegenerative diseases through the modulation of mitophagy and autophagy. By targeting genetically defined pathways, the company aims to create small molecules that restore cellular balance and address the underlying mechanisms of diseases such as Parkinson's disease and amyotrophic lateral sclerosis. Founded in 2018 and based in Cambridge, Massachusetts, Caraway Therapeutics seeks to improve the lives of patients affected by these debilitating conditions by leveraging its expertise in cellular degradation processes. The company was previously known as Rheostat Therapeutics, Inc. before rebranding in October 2019.

Ribometrix

Series A in 2018
Ribometrix, Inc. is a biotechnology company based in Durham, North Carolina, focused on discovering and developing small molecule drugs that target functional three-dimensional RNA structures to treat various human diseases. Established in 2014, the company utilizes advanced expertise in RNA structural analysis to identify novel small molecules that can inhibit the production of proteins associated with diseases. Ribometrix's innovative platform combines proprietary RNA structure determination techniques with cutting-edge RNA tools and artificial intelligence capabilities, allowing researchers to effectively analyze and manipulate RNA biology. The company operates scientific offices in a renovated Biolabs space in Durham, along with additional offices in Chapel Hill and Boston.

Urgent Team

Series D in 2018
Urgent Team Holdings, Inc. operates urgent care centers, offering immediate and primary healthcare services. Their centers serve suburban neighborhoods, rural towns, and underserved communities, providing a wide range of services including treatment for injuries, illnesses, and preventive screenings. They also offer occupational health services and wellness care, ensuring affordable and convenient walk-in medical services for patients.

Xilio Therapeutics

Series A in 2018
Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

Bicycle Therapeutics

Series B in 2018
Bicycle Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel class of medicines known as Bicycles, which are synthetic short peptides designed to stabilize their structural geometry through two loops. The company primarily targets oncology indications with significant unmet medical needs. Its lead product candidate, BT1718, is a Bicycle Toxin Conjugate currently undergoing Phase I/IIa clinical trials aimed at tumors expressing Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies for Nectin-4. Additionally, Bicycle Therapeutics is developing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to advance programs in areas like anti-infectives and cardiovascular health. Founded in 2009, Bicycle Therapeutics is headquartered in Cambridge, United Kingdom.

Artios Pharma

Series B in 2018
Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2015, the company is dedicated to creating first-in-class therapies aimed at selectively killing cancer cells. Artios's product pipeline features several promising programs, including a focus on DNA polymerase theta (Polθ), which plays a crucial role in DNA repair processes. Additionally, the company is advancing an in-licensed program that targets a newly identified protein linked to DDR and is developing a novel treatment aimed at DNA nucleases involved in these pathways. Artios collaborates with Cancer Research Technology and prominent DNA repair researchers globally to enhance its research and development efforts.

Sutro Biopharma

Series E in 2018
Sutro Biopharma is a clinical-stage drug discovery, development, and manufacturing company based in South San Francisco, California. The company specializes in creating next-generation protein therapeutics aimed at treating cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Among its product candidates are STRO-001, an antibody-drug conjugate targeting CD74 for patients with multiple myeloma and non-Hodgkin lymphoma, and STRO-002, which is directed against folate receptor-alpha for individuals with ovarian and endometrial cancers. Sutro Biopharma also has a collaboration and licensing agreement with Celgene Corporation to develop bispecific antibodies and antibody-drug conjugates primarily in the field of immuno-oncology. Founded in 2003, the company continues to advance its innovative therapeutic candidates through rigorous clinical development.

AVROBIO

Series B in 2018
Avrobio is a clinical-stage gene therapy company based in Cambridge, Massachusetts, focused on developing ex vivo lentiviral gene therapies aimed at treating rare diseases with a single-dose approach. The company utilizes hematopoietic stem cells collected from patients, which are modified using a lentiviral vector to insert functional copies of defective genes associated with specific diseases. Avrobio's lead product candidate, AVR-RD-01, is currently in Phase II clinical trials for Fabry disease. Additionally, the company's pipeline includes AVR-RD-02, which has completed preclinical trials for type 1 Gaucher disease; AVR-RD-03, in preclinical development for Pompe disease; and AVR-RD-04, which has also completed preclinical studies for cystinosis. Avrobio has established a research collaboration with Magenta Therapeutics to explore targeted antibody-drug conjugates as a conditioning regimen for its lentiviral gene therapies. Founded in 2015, Avrobio aims to leverage advancements in cell and gene therapies to provide potential cures for serious and debilitating conditions.

Misonix

Post in 2017
Misonix is a leading medical device company specializing in ultrasonic surgical technology. The company designs, manufactures, and markets innovative devices that enhance clinical outcomes in various surgical fields, including neurosurgery, orthopedic surgery, plastic surgery, and wound care. Misonix's product portfolio features advanced ultrasonic platforms such as aspirators for soft and hard tissue removal, instruments for laparoscopic procedures, and devices for wound cleansing and debridement. Additionally, its offerings include tools for precision bone cutting and sculpting, as well as liposuction instruments aimed at improving body aesthetics. Notable products include BoneScalpel, NeXus, Sequel, SonaStar, SonicOne, Theragenesis, TheraSkin, and Therion. Misonix serves a global market, with a presence in regions such as the United States and the United Kingdom, contributing to the overall value of the healthcare system.

Ribometrix

Seed Round in 2017
Ribometrix, Inc. is a biotechnology company based in Durham, North Carolina, focused on discovering and developing small molecule drugs that target functional three-dimensional RNA structures to treat various human diseases. Established in 2014, the company utilizes advanced expertise in RNA structural analysis to identify novel small molecules that can inhibit the production of proteins associated with diseases. Ribometrix's innovative platform combines proprietary RNA structure determination techniques with cutting-edge RNA tools and artificial intelligence capabilities, allowing researchers to effectively analyze and manipulate RNA biology. The company operates scientific offices in a renovated Biolabs space in Durham, along with additional offices in Chapel Hill and Boston.

PanOptica

Series B in 2017
PanOptica, Inc. is a biopharmaceutical company based in Mount Arlington, New Jersey, focused on developing innovative treatments for sight-threatening eye diseases caused by abnormal or leaky blood vessels. Founded in 2009, the company is advancing its lead compound, PAN-90806, a small-molecule selective VEGF receptor antagonist, which shows potential as a topical treatment for conditions such as wet age-related macular degeneration and diabetic retinopathy. By seeking to license and develop novel therapeutics, PanOptica aims to address the limitations of existing treatments and improve patient outcomes in ophthalmology. The company serves pharmaceutical firms and is committed to enhancing the quality of life for patients experiencing vision loss due to these debilitating conditions.

Arsanis

Series D in 2017
Arsanis, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis develops mAbs targeting various bacterial and viral pathogens, including its lead program ASN100, which is focused on preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients and is currently in Phase 2 clinical trials. The company's pipeline also includes ASN500, targeting respiratory syncytial virus (RSV), as well as preclinical candidates ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Additionally, Arsanis operates research and preclinical development efforts in Vienna, Austria, through its subsidiary, Arsanis Biosciences GmbH. The company's advanced understanding of infection pathogenesis and mAb discovery techniques underpins its efforts to tackle significant health challenges posed by infectious diseases.

Pulmocide

Series B in 2017
Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.

CSA Medical

Debt Financing in 2016
CSA Medical, Inc. specializes in the development and manufacturing of spray cryotherapy medical devices. The company's flagship product, the truFreeze device, utilizes cold liquid nitrogen as a cryosurgical tool for the destruction of unwanted tissue in dermatology, gynecology, and general surgery, while facilitating the regrowth of healthy tissue. Additionally, CSA Medical offers the Rapid AV Spray Kit, which enhances the truFreeze system by reducing the time required for liquid nitrogen application. Originally founded as Crymed Technologies in 1993, the company rebranded to CSA Medical in April 2006. Headquartered in Lutherville Timonium, Maryland, CSA Medical also operates a research and development facility in Lexington, Massachusetts.

SUN Behavioral Health

Series A in 2016
SUN Behavioral Health, Inc. is a provider of behavioral health services, operating freestanding hospitals that cater to a diverse population, including children, youth, adults, seniors, women, and military personnel. Founded in 2013 and headquartered in Red Bank, New Jersey, the company offers a comprehensive range of services such as inpatient psychiatric care, substance abuse treatment, partial hospitalization programs, intensive outpatient programs, 24-hour assessments, and crisis stabilization. SUN Behavioral Health works collaboratively with medical and surgical hospitals, healthcare providers, local schools, and community organizations to ensure a seamless continuum of care, focusing on personalized treatment to address significant unmet behavioral health needs.

Cibiem

Debt Financing in 2016
Cibiem Inc. is a medical device company that specializes in the development of minimally invasive, catheter-based technologies for treating diseases mediated by the sympathetic nervous system, including hypertension, heart failure, diabetes, and renal failure. The company focuses on Carotid Body Modulation (CBM), which offers a novel approach to managing these serious health conditions. Founded in 2010 and based in Los Altos, California, with an additional office in Teaneck, New Jersey, Cibiem was co-founded by Mark Gelfand and Howard R. Levin, M.D. The company is supported by prominent venture investors, including Third Rock Ventures and SV Life Sciences, reflecting its innovative potential in the medical device sector.

Bicycle Therapeutics

Series A in 2016
Bicycle Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel class of medicines known as Bicycles, which are synthetic short peptides designed to stabilize their structural geometry through two loops. The company primarily targets oncology indications with significant unmet medical needs. Its lead product candidate, BT1718, is a Bicycle Toxin Conjugate currently undergoing Phase I/IIa clinical trials aimed at tumors expressing Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies for Nectin-4. Additionally, Bicycle Therapeutics is developing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to advance programs in areas like anti-infectives and cardiovascular health. Founded in 2009, Bicycle Therapeutics is headquartered in Cambridge, United Kingdom.

CardioFocus

Debt Financing in 2016
CardioFocus, Inc. is a biotechnology company based in Marlborough, Massachusetts, that specializes in the development of innovative medical devices for the treatment of cardiac disorders, particularly atrial fibrillation. The company offers a range of products, including the HeartLight Endoscopic Ablation System, which utilizes visually guided laser balloon technology to achieve precise pulmonary vein isolation. This system is complemented by the HeartLight Excalibur Balloon, designed for stable contact and effective lesion creation through direct tissue visualization, and the HeartLight X3 System, which allows for controlled lesion formation. CardioFocus focuses on providing electrophysiologists with advanced tools that enhance the precision and control of ablation treatments, utilizing disposable fiber optic catheters for improved visualization of cardiac anatomy and the treatment of arrhythmias. Founded in 1990, CardioFocus continues to pursue advancements in ablation technologies to better meet the needs of patients and healthcare providers.

Artios Pharma

Series A in 2016
Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2015, the company is dedicated to creating first-in-class therapies aimed at selectively killing cancer cells. Artios's product pipeline features several promising programs, including a focus on DNA polymerase theta (Polθ), which plays a crucial role in DNA repair processes. Additionally, the company is advancing an in-licensed program that targets a newly identified protein linked to DDR and is developing a novel treatment aimed at DNA nucleases involved in these pathways. Artios collaborates with Cancer Research Technology and prominent DNA repair researchers globally to enhance its research and development efforts.

AcuFocus

Private Equity Round in 2016
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to restore near vision for presbyopic patients while preserving distance vision. Additionally, AcuFocus develops the IC-8 IOL, a small aperture lens that facilitates a range of vision for patients with cataracts. The AcuTarget HD is another key product, serving as a diagnostic and surgical planning instrument for various vision correction procedures, including LASIK and cataract surgeries. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, addressing the needs of both physicians and patients in the vision care sector. Founded in 2001, AcuFocus continues to focus on innovative solutions for vision-related challenges.

Artios Pharma

Seed Round in 2016
Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2015, the company is dedicated to creating first-in-class therapies aimed at selectively killing cancer cells. Artios's product pipeline features several promising programs, including a focus on DNA polymerase theta (Polθ), which plays a crucial role in DNA repair processes. Additionally, the company is advancing an in-licensed program that targets a newly identified protein linked to DDR and is developing a novel treatment aimed at DNA nucleases involved in these pathways. Artios collaborates with Cancer Research Technology and prominent DNA repair researchers globally to enhance its research and development efforts.

AVROBIO

Series A in 2016
Avrobio is a clinical-stage gene therapy company based in Cambridge, Massachusetts, focused on developing ex vivo lentiviral gene therapies aimed at treating rare diseases with a single-dose approach. The company utilizes hematopoietic stem cells collected from patients, which are modified using a lentiviral vector to insert functional copies of defective genes associated with specific diseases. Avrobio's lead product candidate, AVR-RD-01, is currently in Phase II clinical trials for Fabry disease. Additionally, the company's pipeline includes AVR-RD-02, which has completed preclinical trials for type 1 Gaucher disease; AVR-RD-03, in preclinical development for Pompe disease; and AVR-RD-04, which has also completed preclinical studies for cystinosis. Avrobio has established a research collaboration with Magenta Therapeutics to explore targeted antibody-drug conjugates as a conditioning regimen for its lentiviral gene therapies. Founded in 2015, Avrobio aims to leverage advancements in cell and gene therapies to provide potential cures for serious and debilitating conditions.

SUN Behavioral Health

Series A in 2016
SUN Behavioral Health, Inc. is a provider of behavioral health services, operating freestanding hospitals that cater to a diverse population, including children, youth, adults, seniors, women, and military personnel. Founded in 2013 and headquartered in Red Bank, New Jersey, the company offers a comprehensive range of services such as inpatient psychiatric care, substance abuse treatment, partial hospitalization programs, intensive outpatient programs, 24-hour assessments, and crisis stabilization. SUN Behavioral Health works collaboratively with medical and surgical hospitals, healthcare providers, local schools, and community organizations to ensure a seamless continuum of care, focusing on personalized treatment to address significant unmet behavioral health needs.

Halscion

Debt Financing in 2016
Halscion, Inc. is focused on developing innovative hydrogel scaffolds designed to enhance wound healing and improve scar outcomes. The company produces single-use hydrogel scaffold devices that are injected during surgical procedures at the dermal-subdermal interface of wounds. These biocompatible materials create a structural framework that facilitates the migration and organization of the patient's own healing cells, such as fibroblasts, into the wound. This technology aims to prevent or minimize scar formation, including conditions like keloid and hypertrophic scars. Established in 2005, Halscion is headquartered in Suwanee, Georgia.

Direct Flow Medical

Venture Round in 2016
Direct Flow Medical is a medical device company focused on developing innovative transcatheter aortic valve replacement systems aimed at treating cardiac valve insufficiency. The company’s flagship product is a percutaneous aortic tissue valve prosthesis designed to offer a safe and effective alternative for patients, particularly those over the age of 65 who suffer from calcified aortic valves. Despite the prevalence of this condition, with approximately 1.2 million affected individuals, only around 150,000 receive surgical treatment annually. Direct Flow Medical's technology enhances patient outcomes and minimizes complications by allowing heart surgeons to perform valve replacements without invasive surgery, using repeated assessments of hemodynamic performance prior to final implantation.

PanOptica

Series B in 2016
PanOptica, Inc. is a biopharmaceutical company based in Mount Arlington, New Jersey, focused on developing innovative treatments for sight-threatening eye diseases caused by abnormal or leaky blood vessels. Founded in 2009, the company is advancing its lead compound, PAN-90806, a small-molecule selective VEGF receptor antagonist, which shows potential as a topical treatment for conditions such as wet age-related macular degeneration and diabetic retinopathy. By seeking to license and develop novel therapeutics, PanOptica aims to address the limitations of existing treatments and improve patient outcomes in ophthalmology. The company serves pharmaceutical firms and is committed to enhancing the quality of life for patients experiencing vision loss due to these debilitating conditions.

CardioFocus

Debt Financing in 2016
CardioFocus, Inc. is a biotechnology company based in Marlborough, Massachusetts, that specializes in the development of innovative medical devices for the treatment of cardiac disorders, particularly atrial fibrillation. The company offers a range of products, including the HeartLight Endoscopic Ablation System, which utilizes visually guided laser balloon technology to achieve precise pulmonary vein isolation. This system is complemented by the HeartLight Excalibur Balloon, designed for stable contact and effective lesion creation through direct tissue visualization, and the HeartLight X3 System, which allows for controlled lesion formation. CardioFocus focuses on providing electrophysiologists with advanced tools that enhance the precision and control of ablation treatments, utilizing disposable fiber optic catheters for improved visualization of cardiac anatomy and the treatment of arrhythmias. Founded in 1990, CardioFocus continues to pursue advancements in ablation technologies to better meet the needs of patients and healthcare providers.

AcuFocus

Debt Financing in 2016
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to restore near vision for presbyopic patients while preserving distance vision. Additionally, AcuFocus develops the IC-8 IOL, a small aperture lens that facilitates a range of vision for patients with cataracts. The AcuTarget HD is another key product, serving as a diagnostic and surgical planning instrument for various vision correction procedures, including LASIK and cataract surgeries. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, addressing the needs of both physicians and patients in the vision care sector. Founded in 2001, AcuFocus continues to focus on innovative solutions for vision-related challenges.

Karus Therapeutics

Series B in 2016
Karus Therapeutics Limited is a biopharmaceutical company based in Oxfordshire, United Kingdom, focused on developing innovative small molecule drugs for cancer treatment. Established in 2005, the company specializes in orally-active drugs that target specific molecular pathways. Its portfolio includes KA2237, a dual-selective inhibitor of PI3K isoforms p110ß and p110d, aimed at treating both hematological and solid tumors, and KA2507, which targets HDAC6 for PD-L1 expressing tumors. Karus Therapeutics combines targeted therapies with immunotherapeutic activity, enabling effective treatment of a variety of cancers as well as immune and inflammatory disorders.

Arsanis

Series C in 2016
Arsanis, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis develops mAbs targeting various bacterial and viral pathogens, including its lead program ASN100, which is focused on preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients and is currently in Phase 2 clinical trials. The company's pipeline also includes ASN500, targeting respiratory syncytial virus (RSV), as well as preclinical candidates ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Additionally, Arsanis operates research and preclinical development efforts in Vienna, Austria, through its subsidiary, Arsanis Biosciences GmbH. The company's advanced understanding of infection pathogenesis and mAb discovery techniques underpins its efforts to tackle significant health challenges posed by infectious diseases.

TopiVert

Series A in 2016
TopiVert Ltd. is a clinical-stage biotechnology company based in London, United Kingdom, focused on developing narrow spectrum kinase inhibitors as locally-acting treatments for chronic inflammatory diseases affecting the gastrointestinal tract and the eyes. Founded in 2010, the company is advancing its lead program, TOP1288, which is undergoing a Phase IIa proof of concept study for ulcerative colitis. Additionally, TopiVert is preparing to initiate a Phase I/II study for its second program, TOP1630, aimed at addressing dry eye syndrome. The company's innovative approach enables the delivery of medications at pharmacologically relevant concentrations directly to the targeted areas, potentially leading to improved treatment outcomes for patients.

VHSquared

Series A in 2016
VHsquared Ltd. is a biotechnology company focused on developing oral biologics for immuno-inflammatory conditions affecting the gastrointestinal tract. Founded in 2010 and based in Cambridge, United Kingdom, VHsquared utilizes its proprietary Vorabody platform to create engineered domain antibodies that are resistant to degradation in the gut, allowing for effective oral administration. This innovative approach addresses the limitations of conventional antibodies, which are typically broken down in the gastrointestinal system. The company aims to produce a range of functional food products that target gastrointestinal infections and immune-mediated diseases, leveraging advancements in mucosal immunology and microbiota analysis. By developing therapies that are stable, specific, and locally active, VHsquared seeks to provide safer, more effective treatment options for patients with inflammatory bowel diseases and related conditions.

Arsanis

Debt Financing in 2016
Arsanis, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis develops mAbs targeting various bacterial and viral pathogens, including its lead program ASN100, which is focused on preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients and is currently in Phase 2 clinical trials. The company's pipeline also includes ASN500, targeting respiratory syncytial virus (RSV), as well as preclinical candidates ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Additionally, Arsanis operates research and preclinical development efforts in Vienna, Austria, through its subsidiary, Arsanis Biosciences GmbH. The company's advanced understanding of infection pathogenesis and mAb discovery techniques underpins its efforts to tackle significant health challenges posed by infectious diseases.

Soffio Medical

Series A in 2016
Soffio Medical is a Boston-based company that develops medical devices aimed at treating respiratory diseases. The company's innovative approach focuses on implantable devices designed to implement an airway bypass concept. This technology allows for the venting of trapped air from areas distal to high-resistance airways, which helps to reduce residual lung volume. By alleviating symptoms associated with chronic obstructive pulmonary disease, Soffio Medical's solutions aim to enhance the quality of life for patients suffering from these conditions.

AcuFocus

Debt Financing in 2016
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to restore near vision for presbyopic patients while preserving distance vision. Additionally, AcuFocus develops the IC-8 IOL, a small aperture lens that facilitates a range of vision for patients with cataracts. The AcuTarget HD is another key product, serving as a diagnostic and surgical planning instrument for various vision correction procedures, including LASIK and cataract surgeries. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, addressing the needs of both physicians and patients in the vision care sector. Founded in 2001, AcuFocus continues to focus on innovative solutions for vision-related challenges.

Bicycle Therapeutics

Series A in 2016
Bicycle Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel class of medicines known as Bicycles, which are synthetic short peptides designed to stabilize their structural geometry through two loops. The company primarily targets oncology indications with significant unmet medical needs. Its lead product candidate, BT1718, is a Bicycle Toxin Conjugate currently undergoing Phase I/IIa clinical trials aimed at tumors expressing Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies for Nectin-4. Additionally, Bicycle Therapeutics is developing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to advance programs in areas like anti-infectives and cardiovascular health. Founded in 2009, Bicycle Therapeutics is headquartered in Cambridge, United Kingdom.

Cibiem

Series B in 2016
Cibiem Inc. is a medical device company that specializes in the development of minimally invasive, catheter-based technologies for treating diseases mediated by the sympathetic nervous system, including hypertension, heart failure, diabetes, and renal failure. The company focuses on Carotid Body Modulation (CBM), which offers a novel approach to managing these serious health conditions. Founded in 2010 and based in Los Altos, California, with an additional office in Teaneck, New Jersey, Cibiem was co-founded by Mark Gelfand and Howard R. Levin, M.D. The company is supported by prominent venture investors, including Third Rock Ventures and SV Life Sciences, reflecting its innovative potential in the medical device sector.

Delenex Therapeutics

Venture Round in 2016
Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.

AcuFocus

Debt Financing in 2016
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to restore near vision for presbyopic patients while preserving distance vision. Additionally, AcuFocus develops the IC-8 IOL, a small aperture lens that facilitates a range of vision for patients with cataracts. The AcuTarget HD is another key product, serving as a diagnostic and surgical planning instrument for various vision correction procedures, including LASIK and cataract surgeries. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, addressing the needs of both physicians and patients in the vision care sector. Founded in 2001, AcuFocus continues to focus on innovative solutions for vision-related challenges.

Thesan Pharmaceuticals

Series B in 2016
Thesan Pharmaceuticals, Inc. is a biopharmaceutical company based in Carlsbad, California, established in 2011. It specializes in developing innovative therapeutics for skin disorders, particularly atopic dermatitis and acne. Unlike many companies that primarily reformulate existing treatments with limited advancements, Thesan is dedicated to discovering and developing New Chemical Entities aimed at significantly improving patient outcomes. Through its commitment to innovation, Thesan seeks to address the gaps in dermatological care and provide healthcare providers with effective treatment options for their patients.

PanOptica

Series B in 2016
PanOptica, Inc. is a biopharmaceutical company based in Mount Arlington, New Jersey, focused on developing innovative treatments for sight-threatening eye diseases caused by abnormal or leaky blood vessels. Founded in 2009, the company is advancing its lead compound, PAN-90806, a small-molecule selective VEGF receptor antagonist, which shows potential as a topical treatment for conditions such as wet age-related macular degeneration and diabetic retinopathy. By seeking to license and develop novel therapeutics, PanOptica aims to address the limitations of existing treatments and improve patient outcomes in ophthalmology. The company serves pharmaceutical firms and is committed to enhancing the quality of life for patients experiencing vision loss due to these debilitating conditions.

Doctors of Physical Therapy

Venture Round in 2016
Doctors of Physical Therapy is a physical therapy provider based in Elgin, Illinois, established in 2004. The company offers a wide range of services including sports rehabilitation, post-operative rehabilitation, chronic pain therapy, and manual therapy. It operates clinics in various markets and provides on-site therapy for large employers. Services also encompass injury screening, fall prevention, vestibular therapy, concussion therapy, and specialized rehabilitation techniques. Additionally, Doctors of Physical Therapy offers workers' compensation rehabilitation, expert witness testimony, functional capacity evaluations, and work conditioning. The company focuses on delivering customized treatment plans to meet the individual needs of patients, utilizing both in-clinic and online platforms.

ReShape Medical

Series D in 2015
ReShape Medical Inc. is a medical device company headquartered in San Clemente, California, specializing in non-surgical weight loss solutions. The company offers the ReShape Integrated Dual Balloon System, which employs dual balloon technology to aid weight loss in adults with a Body Mass Index (BMI) of 30-40 who have not achieved success with diet and exercise alone. This procedure is complemented by a personalized weight loss program that lasts one year. The company's product line includes the FDA-approved Lap-Band System, a minimally invasive treatment for obesity, and the investigational ReShape Vest System, designed to wrap around the stomach and induce weight loss without permanently altering patient anatomy. ReShape Medical's portfolio aims to provide effective alternatives to invasive surgical procedures for managing obesity and related metabolic diseases. The company operates as a subsidiary of EnteroMedics Inc., having undergone a name change in 2017.

Avitide

Series C in 2015
Avitide, Inc. is a company that specializes in the discovery, manufacturing, and supply of molecule-specific affinity purification solutions tailored for the biopharmaceutical industry. Founded in 2012 and based in Lebanon, New Hampshire, Avitide focuses on enhancing the purification of therapeutic proteins through its innovative affinity separation technology. This technology helps clients streamline bioprocess development timelines, mitigate program risks, and lower manufacturing costs while ensuring scalability for commercial applications. The company develops customized solutions for a variety of life-saving therapeutics, including enzymes, multi-specific antibodies, gene therapies, and vaccines. By utilizing rapid development techniques for chromatography resins, Avitide aims to improve drug safety and establish bio-similarity in its offerings.

KalVista

Series B in 2015
KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet medical needs. The company's primary focus is on plasma kallikrein inhibitors aimed at treating hereditary angioedema (HAE) and diabetic macular edema (DME), which is a leading cause of vision loss in adults. KalVista's product pipeline includes KVD001, KVD900, and KVD824, which are designed to provide innovative therapeutic options for patients who may not respond adequately to existing treatments. The company also has a preclinical program exploring a novel oral Factor XIIa inhibitor. With over two decades of expertise in serine protease inhibitor research, KalVista is positioned to address critical gaps in treatment for these conditions.

Autifony Therapeutics

Series A in 2015
Autifony Therapeutics Limited is a biotechnology company based in London, United Kingdom, focused on developing innovative medicines for hearing disorders, including hearing loss and tinnitus. Established in 2011, the company leverages a drug discovery platform aimed at addressing unmet medical needs in this area. In addition to its primary focus on hearing-related conditions, Autifony's platform is also designed to alleviate symptoms associated with central nervous system disorders such as schizophrenia, fragile X syndrome, and Alzheimer's disease. By concentrating on these conditions, Autifony Therapeutics aims to provide effective treatment options for patients suffering from a range of debilitating disorders.

Schweiger Dermatology Group

Series A in 2015
Schweiger Dermatology Group, PLLC is a prominent dermatology practice that operates medical, cosmetic, and surgical dermatology facilities across New York and New Jersey. Founded in 2010 and based in New York City, the group offers a comprehensive range of services, including treatments for various skin conditions such as acne, psoriasis, eczema, and skin cancer screenings. In addition to medical care, it provides an array of cosmetic services, including facial rejuvenation, laser resurfacing, and body contouring, as well as plastic surgery options like breast augmentation and liposuction. The practice is staffed by board-certified dermatologists, physician assistants, and a plastic surgeon, ensuring high-quality care tailored to individual skin care needs. Schweiger Dermatology Group also offers a selection of skin care products, including cleansers and serums, further supporting its commitment to comprehensive dermatological health.

U.S. Renal Care

Private Equity Round in 2015
U.S. Renal Care, Inc. is a healthcare service provider specializing in dialysis for patients with chronic kidney failure. Established in 2000 and headquartered in Plano, Texas, the company operates a network of 335 dialysis facilities across 32 states and the Territory of Guam, serving over 25,000 patients. U.S. Renal Care offers a range of services, including in-center hemodialysis, at-home hemodialysis, and peritoneal dialysis, specifically catering to those with end-stage renal disease. In addition to its outpatient and home dialysis programs, the company collaborates with local community hospitals to manage acute setting dialysis programs. U.S. Renal Care also provides support for families, caregivers, and physicians involved in patient care, operating with a business model that includes partnerships with local nephrologists.

Direct Flow Medical

Private Equity Round in 2014
Direct Flow Medical is a medical device company focused on developing innovative transcatheter aortic valve replacement systems aimed at treating cardiac valve insufficiency. The company’s flagship product is a percutaneous aortic tissue valve prosthesis designed to offer a safe and effective alternative for patients, particularly those over the age of 65 who suffer from calcified aortic valves. Despite the prevalence of this condition, with approximately 1.2 million affected individuals, only around 150,000 receive surgical treatment annually. Direct Flow Medical's technology enhances patient outcomes and minimizes complications by allowing heart surgeons to perform valve replacements without invasive surgery, using repeated assessments of hemodynamic performance prior to final implantation.

Ximedica

Acquisition in 2014
Ximedica has been a prominent player in the medical device industry for over 30 years, offering comprehensive research, development, regulatory, and manufacturing services. The company specializes in device and systems design, employing a human-centered, vertically integrated approach to enhance product efficiency from conception to market delivery. Ximedica's experienced, cross-disciplinary teams address complex development challenges, enabling clients to explore new market opportunities and achieve award-winning designs while exceeding sales targets. The firm emphasizes quality and regulatory assurance, underscored by its ISO 13485:2003 certification, which reflects its commitment to maintaining high standards in medical device innovation.

Bicycle Therapeutics

Series A in 2014
Bicycle Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel class of medicines known as Bicycles, which are synthetic short peptides designed to stabilize their structural geometry through two loops. The company primarily targets oncology indications with significant unmet medical needs. Its lead product candidate, BT1718, is a Bicycle Toxin Conjugate currently undergoing Phase I/IIa clinical trials aimed at tumors expressing Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies for Nectin-4. Additionally, Bicycle Therapeutics is developing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to advance programs in areas like anti-infectives and cardiovascular health. Founded in 2009, Bicycle Therapeutics is headquartered in Cambridge, United Kingdom.

AcuFocus

Venture Round in 2014
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to restore near vision for presbyopic patients while preserving distance vision. Additionally, AcuFocus develops the IC-8 IOL, a small aperture lens that facilitates a range of vision for patients with cataracts. The AcuTarget HD is another key product, serving as a diagnostic and surgical planning instrument for various vision correction procedures, including LASIK and cataract surgeries. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, addressing the needs of both physicians and patients in the vision care sector. Founded in 2001, AcuFocus continues to focus on innovative solutions for vision-related challenges.

CardioFocus

Debt Financing in 2014
CardioFocus, Inc. is a biotechnology company based in Marlborough, Massachusetts, that specializes in the development of innovative medical devices for the treatment of cardiac disorders, particularly atrial fibrillation. The company offers a range of products, including the HeartLight Endoscopic Ablation System, which utilizes visually guided laser balloon technology to achieve precise pulmonary vein isolation. This system is complemented by the HeartLight Excalibur Balloon, designed for stable contact and effective lesion creation through direct tissue visualization, and the HeartLight X3 System, which allows for controlled lesion formation. CardioFocus focuses on providing electrophysiologists with advanced tools that enhance the precision and control of ablation treatments, utilizing disposable fiber optic catheters for improved visualization of cardiac anatomy and the treatment of arrhythmias. Founded in 1990, CardioFocus continues to pursue advancements in ablation technologies to better meet the needs of patients and healthcare providers.

Thesan Pharmaceuticals

Series B in 2014
Thesan Pharmaceuticals, Inc. is a biopharmaceutical company based in Carlsbad, California, established in 2011. It specializes in developing innovative therapeutics for skin disorders, particularly atopic dermatitis and acne. Unlike many companies that primarily reformulate existing treatments with limited advancements, Thesan is dedicated to discovering and developing New Chemical Entities aimed at significantly improving patient outcomes. Through its commitment to innovation, Thesan seeks to address the gaps in dermatological care and provide healthcare providers with effective treatment options for their patients.

AqueSys

Series D in 2014
AqueSys, Inc. is an ophthalmic company based in Aliso Viejo, California, specializing in the development and commercialization of innovative implantable devices for glaucoma treatment. Founded in 2005, the company is known for its XEN gel stent, which facilitates the outflow of aqueous fluid from the anterior chamber to the subconjunctival space, effectively lowering intraocular pressure. This device creates a new drainage pathway, enhancing patient outcomes in glaucoma management. AqueSys operates as a subsidiary of Allergan plc, focusing on advancing surgical solutions to improve eye health.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.